Grant: Engage Grants Program
University of Saskatchewan
$25,000.00
Application of Accutas Hydrogel Technology for Gonorrhoea Diagnosis and No/Go Decision for Ciprofloxacin Use at Point of Care
EF 2015-16
Résumé
The ""Accutas"" technology developed by Aquila Diagnostic Systems Inc., Edmonton is a rapid point-of-care
hydrogel-based diagnostic platform that has earlier successfully detected blood-borne infectious diseases such
as malaria and bovine/porcine pathogens. The company is now contemplating its use in detecting antibiotic
resistant sexually transmitted infections (STIs e.g. N. gonorrhoeae) which will be revolutionary, given the
emergence of many multidrug/totally drug resistant bacteria in recent times. However, the company is faced
with some key challenges that include: 1) No scientific expertise in the field of STIs; 2) No access to diagnostic
biomarkers of N. gonorrhoeae and its susceptibility to antibiotic (e.g. ciprofloxacin) or expertise to discover the
same; 3) No prior experience of developing a diagnostic test using urine/cervical swab samples and for
detecting antibiotic resistance. The proposed project aims to solve these problems by developing a diagnostic
technique for detecting N. gonorrhoeae and ciprofloxacin resistance from clinical samples that will be
compatible with Accutas hydrogel-based technology. This technique is based on Polymerase Chain Reaction
(PCR)-based amplification/identification of specific genetic markers of N. gonorrhoeae and resistance. This
will involve use of novel probes indigenously developed in the applicant's lab and standardization experiments
to ensure high level of specificity and sensitivity. Further, the standardized technique will be incorporated in
the ""Accutas"" test device followed by more refinements and validation test runs. The company will benefit
immensely by this research alliance with the applicant, Prof Jo-Anne Dillon who is known for her work in the
area of STIs and antibiotic resistance. In very near future, we envisage an effective test for N. gonorrhoeae
treatment that would stop transmission at the point of care and facilitate reduced health costs with the prudent
use of antimicrobial agents.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
484613-2015
Name nom
Dillon, JoAnne
Department département
Biology
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Application of Accutas Hydrogel Technology for Gonorrhoea Diagnosis and No/Go Decision for Ciprofloxacin Use at Point of Care
Keyword
NSERC
Application summary
The ""Accutas"" technology developed by Aquila Diagnostic Systems Inc., Edmonton is a rapid point-of-care
hydrogel-based diagnostic platform that has earlier successfully detected blood-borne infectious diseases such
as malaria and bovine/porcine pathogens. The company is now contemplating its use in detecting antibiotic
resistant sexually transmitted infections (STIs e.g. N. gonorrhoeae) which will be revolutionary, given the
emergence of many multidrug/totally drug resistant bacteria in recent times. However, the company is faced
with some key challenges that include: 1) No scientific expertise in the field of STIs; 2) No access to diagnostic
biomarkers of N. gonorrhoeae and its susceptibility to antibiotic (e.g. ciprofloxacin) or expertise to discover the
same; 3) No prior experience of developing a diagnostic test using urine/cervical swab samples and for
detecting antibiotic resistance. The proposed project aims to solve these problems by developing a diagnostic
technique for detecting N. gonorrhoeae and ciprofloxacin resistance from clinical samples that will be
compatible with Accutas hydrogel-based technology. This technique is based on Polymerase Chain Reaction
(PCR)-based amplification/identification of specific genetic markers of N. gonorrhoeae and resistance. This
will involve use of novel probes indigenously developed in the applicant's lab and standardization experiments
to ensure high level of specificity and sensitivity. Further, the standardized technique will be incorporated in
the ""Accutas"" test device followed by more refinements and validation test runs. The company will benefit
immensely by this research alliance with the applicant, Prof Jo-Anne Dillon who is known for her work in the
area of STIs and antibiotic resistance. In very near future, we envisage an effective test for N. gonorrhoeae
treatment that would stop transmission at the point of care and facilitate reduced health costs with the prudent
use of antimicrobial agents.